Primary graft dysfunction (PGD) is a common complication after lung transplantation associated with poor outcomes. Although risk factors have been identified, the complex interactions between clinical variables affecting PGD risk are not well understood, which can complicate decisions about donor-lung acceptance. Previously, we developed a machine learning model to predict grade 3 PGD using donor and recipient electronic health record data, but it lacked granular information from donor-lung computed tomography (CT) scans, which are routinely assessed during offer review. In this study, we used a gated approach to determine optimal methods for analyzing donor-lung CT scans among patients receiving first-time, bilateral lung transplants at a single center over 10 years. We assessed 4 computer vision approaches and fused the best with electronic health record data at 3 points in the machine learning process. A total of 160 patients had donor-lung CT scans for analysis. The best imaging-only approach employed a 3D ResNet model, yielding median (interquartile range) areas under the receiver operating characteristic and precision-recall curves of 0.63 (0.49-0.72) and 0.48 (0.35-0.6), respectively. Combining imaging with clinical data using late fusion provided the highest performance, with median areas under the receiver operating characteristic and precision-recall curves of 0.74 (0.59-0.85) and 0.61 (0.47-0.72), respectively.

The integration of advanced imaging and artificial intelligence technologies in radiation therapy has revolutionized cancer treatment by enhancing precision and adaptability. This study introduces a novel dual-energy computed tomography (DECT) guided intelligent radiation therapy (DEIT) platform designed to streamline and optimize the radiation therapy process. The DEIT system combines DECT, a newly designed dual-layer multileaf collimator, deep learning algorithms for auto-segmentation, and automated planning and quality assurance capabilities. The DEIT system integrates an 80-slice computed tomography (CT) scanner with an 87 cm bore size, a linear accelerator delivering 4 photon and 5 electron energies, and a flat panel imager optimized for megavoltage (MV) cone beam CT acquisition. A comprehensive evaluation of the system's accuracy was conducted using end-to-end tests. Virtual monoenergetic CT images and electron density images of the DECT were generated and compared on both phantom and patient. The system's auto-segmentation algorithms were tested on 5 cases for each of the 99 organs at risk, and the automated optimization and planning capabilities were evaluated on clinical cases. The DEIT system demonstrated systematic errors of less than 1 mm for target localization. DECT reconstruction showed electron density mapping deviations ranging from -0.052 to 0.001, with stable Hounsfield unit consistency across monoenergetic levels above 60 keV, except for high-Z materials at lower energies. Auto-segmentation achieved dice similarity coefficients above 0.9 for most organs with an inference time of less than 2 seconds. Dose-volume histogram comparisons showed improved dose conformity indices and reduced doses to critical structures in auto-plans compared to manual plans across various clinical cases. In addition, high gamma passing rates at 2%/2 mm in both 2-dimensional (above 97%) and 3-dimensional (above 99%) in vivo analyses further validate the accuracy and reliability of treatment plans. The DEIT platform represents a viable solution for radiation treatment. The DEIT system uses artificial intelligence-driven automation, real-time adjustments, and CT imaging to enhance the radiation therapy process, improving efficiency and flexibility.

This clinical trial examined how the articifial intelligence (AI)-based diagnostics system S-Detect for Thyroid influences the ultrasound diagnostic work-up of thyroid ultrasound (US) performed by different US users in clinical practice and how different US users influences the diagnostic accuracy of S-Detect. We conducted a clinical trial with 20 participants, including medical students, US novice physicians, and US experienced physicians. Five patients with thyroid nodules (one malignant and four benign) volunteered to undergo a thyroid US scan performed by all 20 participants using the same US systems with S-Detect installed. Participants performed a focused thyroid US on each patient case and made a nodule classification according to the European Thyroid Imaging Reporting And Data System (EU-TIRADS). They then performed a S-Detect analysis of the same nodule and were asked to re-evaluate their EU-TIRADS reporting. From the EU-TIRADS assessments by participants, we derived a biopsy recommendation outcome of whether fine needle aspiration biopsy (FNAB) was recommended. The mean diagnostic accuracy for S-Detect was 71.3% (range 40-100%) among all participants, with no significant difference between the groups (p = 0.31). The accuracy of our biopsy recommendation outcome was 69.8% before and 69.2% after AI for all participants (p = 0.75). In this trial, we did not find S-Detect to improve the thyroid diagnostic work-up in clinical practice among novice and intermediate ultrasound operators. However, the operator had a substantial impact on the AI-generated ultrasound diagnosis, with a variation in diagnostic accuracy from 40 to 100%, despite the same patients and ultrasound machines being used in the trial.

Gallbladder cancer (GBC) is the most common malignant tumor in the biliary system, characterized by high malignancy, aggressiveness, and poor prognosis. Early diagnosis holds paramount importance in ameliorating therapeutic outcomes. Presently, the clinical diagnosis of GBC primarily relies on clinical-radiological-pathological approach. However, there remains a potential for missed diagnosis and misdiagnose in the realm of clinical practice. We firstly analyzed the blood-based biomarkers, such as carcinoembryonic antigen and carbohydrate antigen 19-9. Subsequently, we evaluated the diagnostic performance of various imaging modalities, including ultrasound (US), endoscopic ultrasound (EUS), computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography/computed tomography (PET/CT) and pathological examination, emphasizing their strengths and limitations in detecting early-stage GBC. Furthermore, we explored the potential of emerging technologies, particularly artificial intelligence (AI) and liquid biopsy, to revolutionize GBC diagnosis. AI algorithms have demonstrated improved image analysis capabilities, while liquid biopsy offers the promise of non-invasive and real-time monitoring. However, the translation of these advancements into clinical practice necessitates further validation and standardization. The review highlighted the advantages and limitations of current diagnostic approaches and underscored the need for innovative strategies to enhance diagnostic accuracy of GBC. In addition, we emphasized the importance of multidisciplinary collaboration to improve early diagnosis of GBC and ultimately patient outcomes. This review endeavoured to impart fresh perspectives and insights into the early diagnosis of GBC.

Whole-body PET imaging plays an essential role in cancer diagnosis and treatment but suffers from low image quality. Traditional deep learning-based denoising methods work well for a specific acquisition but are less effective in handling diverse PET protocols. In this study, we proposed and validated a 3D Denoising Diffusion Probabilistic Model (3D DDPM) as a robust and universal solution for whole-body PET image denoising. The proposed 3D DDPM gradually injected noise into the images during the forward diffusion phase, allowing the model to learn to reconstruct the clean data during the reverse diffusion process. A 3D convolutional network was trained using high-quality data from the Biograph Vision Quadra PET/CT scanner to generate the score function, enabling the model to capture accurate PET distribution information extracted from the total-body datasets. The trained 3D DDPM was evaluated on datasets from four scanners, four tracer types, and six dose levels representing a broad spectrum of clinical scenarios. The proposed 3D DDPM consistently outperformed 2D DDPM, 3D UNet, and 3D GAN, demonstrating its superior denoising performance across all tested conditions. Additionally, the model's uncertainty maps exhibited lower variance, reflecting its higher confidence in its outputs. The proposed 3D DDPM can effectively handle various clinical settings, including variations in dose levels, scanners, and tracers, establishing it as a promising foundational model for PET image denoising. The trained 3D DDPM model of this work can be utilized off the shelf by researchers as a whole-body PET image denoising solution. The code and model are available at https://github.com/Miche11eU/PET-Image-Denoising-Using-3D-Diffusion-Model .

To address the challenges of verifying MR-based attenuation correction (MRAC) in PET/MR due to CT positional mismatches and alignment issues, this study utilized a flatbed insert and arms-down positioning during PET/CT scans to achieve precise MR-CT matching for accurate MRAC evaluation. A validation dataset of 21 patients underwent whole-body [¹⁸F]FDG PET/CT followed by [¹⁸F]FDG PET/MR. A flatbed insert ensured consistent positioning, allowing direct comparison of four MRAC methods-four-tissue and five-tissue models with discrete and continuous μ-maps-against CT-based attenuation correction (CTAC). A deep learning-based framework, trained on a dataset of 300 patients, was used to generate synthesized-CTs from MR images, forming the basis for all MRAC methods. Quantitative analyses were conducted at the whole-body, region of interest, and lesion levels, with lesion-distance analysis evaluating the impact of bone proximity on standardized uptake value (SUV) quantification. Distinct differences were observed among MRAC methods in spine and femur regions. Joint histogram analysis showed MRAC-4 (continuous μ-map) closely aligned with CTAC. Lesion-distance analysis revealed MRAC-4 minimized bone-induced SUV interference (r = 0.01, p = 0.8643). However, tissues prone to bone segmentation interference, such as the spine and liver, exhibited greater SUV variability and lower reproducibility in MRAC-4 compared to MRAC-2 (2D bone segmentation, discrete μ-map) and MRAC-3 (3D bone segmentation, discrete μ-map). Using a flatbed insert, this study validated MRAC with high precision. Continuous μ-value MRAC method (MRAC-4) demonstrated superior accuracy and minimized bone-related SUV errors but faced challenges in reproducibility, particularly in bone-rich regions.

Large language models (LLMs) show promise in radiological diagnosis, but their performance may be affected by the context of the cases presented. Our purpose is to investigate how providing information about prior probabilities influences the diagnostic performance of an LLM in radiological quiz cases. We analyzed 322 consecutive cases from Radiology's "Diagnosis Please" quiz using Claude 3.5 Sonnet under three conditions: without context (Condition 1), informed as quiz cases (Condition 2), and presented as primary care cases (Condition 3). Diagnostic accuracy was compared using McNemar's test. The overall accuracy rate significantly improved in Condition 2 compared to Condition 1 (70.2% vs. 64.9%, p = 0.029). Conversely, the accuracy rate significantly decreased in Condition 3 compared to Condition 1 (59.9% vs. 64.9%, p = 0.027). Providing information that may influence prior probabilities significantly affects the diagnostic performance of the LLM in radiological cases. This suggests that LLMs may incorporate Bayesian-like principles and adjust the weighting of their diagnostic responses based on prior information, highlighting the potential for optimizing LLM's performance in clinical settings by providing relevant contextual information.

To investigate the effect of CT enhancement phase on radiomics features for predicting post-surgical recurrence of clear cell renal cell carcinoma (ccRCC). This retrospective study included 144 patients who underwent radical or partial nephrectomy for ccRCC. Preoperative multiphase abdominal CT scans (non-contrast, corticomedullary, and nephrographic phases) were obtained for each patient. Automated segmentation of renal masses was performed using the nnU-Net framework. Radiomics signatures (RS) were developed for each phase using ensembles of machine learning-based models (Random Survival Forests [RSF], Survival Support Vector Machines [S-SVM], and Extreme Gradient Boosting [XGBoost]) with and without feature selection. Feature selection was performed using Affinity Propagation Clustering. The primary endpoint was disease-free survival, assessed by concordance index (C-index). The study included 144 patients. Radical and partial nephrectomies were performed in 81% and 19% of patients, respectively, with 81% of tumors classified as high grade. Disease recurrence occurred in 74 patients (51%). A total of 1,316 radiomics features were extracted per phase per patient. Without feature selection, C-index values for RSF, S-SVM, XGBoost, and Penalized Cox models ranged from 0.43 to 0.61 across phases. With Affinity Propagation feature selection, C-index values improved to 0.51-0.74, with the corticomedullary phase achieving the highest performance (C-index up to 0.74). The results of our study indicate that radiomics analysis of corticomedullary phase contrast-enhanced CT images may provide valuable predictive insight into recurrence risk for non-metastatic ccRCC following surgical resection. However, the lack of external validation is a limitation, and further studies are needed to confirm these findings in independent cohorts.

To compare the diagnostic performance and image quality of a deep-learning-assisted ultra-fast biparametric MRI (bpMRI) with the conventional multiparametric MRI (mpMRI) for the diagnosis of clinically significant prostate cancer (csPCa). This prospective single-center study enrolled 123 biopsy-naïve patients undergoing conventional mpMRI and additionally ultra-fast bpMRI at 3 T between 06/2023-02/2024. Two radiologists (R1: 4 years and R2: 3 years of experience) independently assigned PI-RADS scores (PI-RADS v2.1) and assessed image quality (mPI-QUAL score) in two blinded study readouts. Weighted Cohen's Kappa (κ) was calculated to evaluate inter-reader agreement. Diagnostic performance was analyzed using clinical data and histopathological results from clinically indicated biopsies. Inter-reader agreement was good for both mpMRI (κ = 0.83) and ultra-fast bpMRI (κ = 0.87). Both readers demonstrated high sensitivity (≥94 %/≥91 %, R1/R2) and NPV (≥96 %/≥95 %) for csPCa detection using both protocols. The more experienced reader mostly showed notably higher specificity (≥77 %/≥53 %), PPV (≥62 %/≥45 %), and diagnostic accuracy (≥82 %/≥65 %) compared to the less experienced reader. There was no significant difference in the diagnostic performance of correctly identifying csPCa between both protocols (p > 0.05). The ultra-fast bpMRI protocol had significantly better image quality ratings (p < 0.001) and achieved a reduction in scan time of 80 % compared to conventional mpMRI. Deep-learning-assisted ultra-fast bpMRI protocols offer a promising alternative to conventional mpMRI for diagnosing csPCa in biopsy-naïve patients with comparable inter-reader agreement and diagnostic performance at superior image quality. However, reader experience remains essential for diagnostic performance.

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by intracellular neurofibrillary tangles with tau protein and extracellular β-amyloid plaques. Early and accurate diagnosis is crucial for effective treatment and management. The purpose of this review is to investigate new technologies that improve diagnostic accuracy while looking at the current diagnostic criteria for AD, such as clinical evaluations, cognitive testing, and biomarker-based techniques. A thorough review of the literature was done in order to assess both conventional and contemporary diagnostic methods. Multimodal strategies integrating clinical, imaging, and biochemical evaluations were emphasised. The promise of current developments in biomarker discovery was also examined, including mass spectrometry and artificial intelligence. Current diagnostic approaches include cerebrospinal fluid (CSF) biomarkers, imaging tools (MRI, PET), cognitive tests, and new blood-based markers. Integrating these technologies into multimodal diagnostic procedures enhances diagnostic accuracy and distinguishes dementia from other conditions. New technologies that hold promise for improving biomarker identification and diagnostic reliability include mass spectrometry and artificial intelligence. Advancements in AD diagnostics underscore the need for accessible, minimally invasive, and cost-effective techniques to facilitate early detection and intervention. The integration of novel technologies with traditional methods may significantly enhance the accuracy and feasibility of AD diagnosis.